Drotrecogin alfa Side Effects
Applies to drotrecogin alfa: intravenous powder for solution.
Serious side effects of Drotrecogin alfa
Along with its needed effects, drotrecogin alfa may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking drotrecogin alfa:
More common
- Bleeding
For Healthcare Professionals
Applies to drotrecogin alfa: intravenous powder for injection.
General
The most common side effect associated with drotrecogin alfa has been bleeding.[Ref]
Hematologic
Hematologic side effects have most commonly included bleeding (25% vs 18% with placebo). The majority of events were ecchymoses or gastrointestinal tract bleeding. Serious bleeding has been reported in 3.5% of patients (vs 2% with placebo) and included intracranial hemorrhage, life threatening hemorrhage, and any event requiring 3 or more units of packed red blood cells per days for 2 consecutive days.[Ref]
Serious bleeding events have been reported at the following sites: Gastrointestinal, intra-abdominal, intrathoracic, retroperitoneal, intracranial, genitourinary, skin or soft tissues.[Ref]
More about drotrecogin alfa
- Check interactions
- Compare alternatives
- Reviews (1)
- Dosage information
- During pregnancy
- Drug class: miscellaneous coagulation modifiers
Professional resources
Other brands
Related treatment guides
References
1. Product Information. Xigris (drotrecogin alfa). Lilly, Eli and Company. 2001.
2. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
